3-[(3S,4S)-4-acetamido-3-methylpentyl]-2-amino-12-oxo-N-(1,3-thiazol-5-ylmethyl)-1-azatricyclo[6.4.1.04,13]trideca-4,6,8(13)-triene-2-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-[(3S,4S)-4-acetamido-3-methylpentyl]-2-amino-12-oxo-N-(1,3-thiazol-5-ylmethyl)-1-azatricyclo[6.4.1.04,13]trideca-4,6,8(13)-triene-2-carboxamide
• 化学式: C₂₅H₃₃N₅O₃S
• 分子量: 483.6
• InChiKey: RBEZGHUVGJRXKT-FNCXHSLPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  146
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• [EN] METHODS AND COMPOSITIONS FOR THE INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR ACTIVITY AND VASCULAR PERMEABILITY<br/>[FR] MÉTHODES ET COMPOSITIONS POUR L'INHIBITION DE L'ACTIVITÉ DU FACTEUR DE CROISSANCE DE L'ENDOTHÉLIUM VASCULAIRE ET DE LA PERMÉABILITÉ VASCULAIRE
  申请人：UNIV BRITISH COLUMBIA

  公开号：WO2014139014A1

  公开（公告）日：2014-09-18

  Methods of altering microenvironmental levels of Vascular Endothelial Growth Factor in a subject are disclosed. The methods include providing a Granzyme B (GzmB) inhibitor to an area of inflammation. The area of inflammation can be associated with conditions that have an associated increase in vascular permeability, including for example, rheumatoid arthritis, myocardial infarction, ocular disease, skin conditions, such as psoriasis, and dermatitis, cancer, transplantation, and/or arthrosclerosis, and the like. The Granzyme B inhibitor can be comprised of, but not limited to, a nucleic acid, a polypeptide, a Granzyme B specific antibody, a Granzyme B antibody derivative, or a small molecule.